Protalix BioTherapeuticsPLX
PLX
About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Employees: 213
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
405% more call options, than puts
Call options by funds: $838K | Put options by funds: $166K
360% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 5
149% more capital invested
Capital invested by funds: $8.4M [Q4 2024] → $21M (+$12.6M) [Q1 2025]
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
40% more funds holding
Funds holding: 45 [Q4 2024] → 63 (+18) [Q1 2025]
4.52% more ownership
Funds ownership: 5.97% [Q4 2024] → 10.49% (+4.52%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for PLX.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARMIEL, Israel , May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York.
Neutral
Seeking Alpha
1 month ago
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript
Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Officer Eyal Rubin – Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten – Zacks Operator Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded.
Positive
Proactive Investors
1 month ago
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth
Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout treatment PRX-115 later this year, as the company builds on momentum from positive early-stage results and rising product sales. The Israeli biopharmaceutical firm reported first-quarter revenues from product sales of $10 million, up 170% from a year earlier, driven largely by higher sales to Pfizer and Brazil's Fiocruz.
Neutral
PRNewsWire
1 month ago
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update.
Neutral
PRNewsWire
1 month ago
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025.
Positive
Seeking Alpha
2 months ago
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with increasing royalties expected, and the company has achieved a debt-free status and profitability. PRX-115 shows promise for gout treatment, potentially outperforming KRYSTEXXA, while PRX-119 targets NETs but remains speculative.
Neutral
PRNewsWire
2 months ago
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
CARMIEL, Israel , March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025. iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors.
Positive
Proactive Investors
2 months ago
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline - ICYMI
Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the company's unique approach to drug manufacturing using plant cells instead of mammalian cells. He explained that this method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech space.
Positive
Proactive Investors
2 months ago
Protalix Biotherapeutics gains momentum: analysts see long-term upside
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio, to partner Chiesi Rare Disease. The company's improving financial position and revenue outlook have analysts projecting further upside following the release of its full year 2024 results.
Positive
Proactive Investors
2 months ago
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate
Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships, and provided updates on its clinical pipeline, including a promising gout treatment candidate. The biopharmaceutical company recorded $53 million in product revenue for the year ended December 31, 2024, a 31% increase from $40.4 million in 2023, with gains from sales to Chiesi, Pfizer, and Brazil.
Charts implemented using Lightweight Charts™